S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Expert Warns FBI: “New Panic is Coming in 2023” (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:NCNA

NuCana - NCNA Stock Forecast, Price & News

$1.54
-0.05 (-3.14%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.52
$1.60
50-Day Range
$0.66
$1.62
52-Week Range
$0.52
$3.31
Volume
48,370 shs
Average Volume
136,656 shs
Market Capitalization
$80.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67

NuCana MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
138.1% Upside
$3.67 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

452nd out of 1,026 stocks

Pharmaceutical Preparations Industry

216th out of 504 stocks

NCNA stock logo

About NuCana (NASDAQ:NCNA) Stock

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Stock News Headlines

3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
3 Secrets To Consistent Trading Success
Don't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. pixel
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NCNA Company Calendar

Last Earnings
11/16/2022
Today
2/08/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NCNA
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+138.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-55,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.73 per share

Miscellaneous

Free Float
35,900,000
Market Cap
$80.36 million
Optionable
Not Optionable
Beta
1.33

Key Executives

  • Hugh Stephen Griffith
    Chief Executive Officer & Executive Director
  • Donald Munoz
    Chief Financial Officer
  • Elisabeth Oelmann
    Senior VP-Medical & Clinical Development
  • Jeffrey D. Bloss
    Chief Medical Officer
  • Theresa Margaret Bruce
    Senior Vice President-Clinical Operations













NCNA Stock - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings
or view top-rated stocks.

What is NuCana's stock price forecast for 2023?

2 equities research analysts have issued twelve-month price objectives for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 132.1% from the stock's current price.
View analysts price targets for NCNA
or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2023?

NuCana's stock was trading at $0.66 at the start of the year. Since then, NCNA shares have increased by 139.4% and is now trading at $1.58.
View the best growth stocks for 2023 here
.

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our NCNA earnings forecast
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) released its earnings results on Wednesday, November, 16th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02.

What other stocks do shareholders of NuCana own?
When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $1.58.

How much money does NuCana make?

NuCana (NASDAQ:NCNA) has a market capitalization of $82.44 million. The company earns $-55,740,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:NCNA) was last updated on 2/9/2023 by MarketBeat.com Staff